查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2001067

胃癌治療市場：2026-2032年全球市場預測（依治療方法、給藥途徑、分期、通路和最終用戶分類）

Stomach Cancer Treatment Market by Treatment Type, Route Of Administration, Stage, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，胃癌治療市場價值將達到 61 億美元，到 2026 年將成長至 67.1 億美元，到 2032 年將達到 127.9 億美元，複合年成長率為 11.16%。

主要市場統計數據
基準年 2025 61億美元
預計年份：2026年 67.1億美元
預測年份 2032 127.9億美元
複合年成長率 (%) 11.16%

全面概述了影響醫療實踐的胃癌治療趨勢、未滿足的需求、治療方法創新和相關人員的優先事項。

胃癌治療正處於一個轉捩點，數十年來逐步改進的成果與治療創新和醫療體系重組的新趨勢交匯融合。患者、臨床醫生和保險公司正在探索日益複雜的治療方案，這些方案將手術和化療等傳統治療方法與標靶治療、免疫腫瘤療法和先進放射治療技術的廣泛應用相結合。因此，臨床決策流程現在需要整合組織學亞型、分子譜分析以及以患者為中心的因素，例如給藥途徑和醫療環境。

科學突破、不斷發展的管理實踐以及醫療保健系統的發展趨勢如何重塑胃癌治療的臨床路徑和投資重點。

科學突破、臨床實務進步以及醫療服務體系的系統性變革，共同推動著胃癌治療的轉型。精準醫學的進步加速了治療標靶的識別，為將EGFR、HER2和VEGF抑制劑等標靶治療納入標準治療方案創造了契機。同時，包括CTLA-4和PD-1抑制劑在內的免疫療法，正在重新定義特定患者群體持續療效的預期，促使人們重新評估終點指標的選擇以及長期療效的評估方法。

整體近期美國關稅調整如何影響胃癌治療的供應鏈韌性、籌資策略和採購慣例進行定性分析。

政策變更和貿易措施會對藥品供應鏈、採購成本和製造商定價策略產生連鎖反應，並可能對治療方法的可近性和可近性產生重大影響。美國近期提出的關稅提案和調整凸顯了直接成本差異之外的其他因素，包括供應商多元化、合約條款和庫存策略。由於許多活性成分和成品依賴全球生產網路，關稅帶來的成本壓力可能會加速企業將生產遷回本國、尋找替代供應商或重新談判長期合約以緩解投入成本波動的措施。

詳細的細分分析顯示治療方法、給藥途徑、分銷管道、疾病階段、最終用戶和組織類型如何共同決定治療和商業策略。

精細的細分觀點闡明了治療決策和商業策略如何與臨床異質性和臨床實踐的實際情況相契合。治療方法包括化療、免疫療法、放射線治療、手術和標靶治療，每種療法包含具有臨床意義的亞群。治療方法包括Fluorouracil、鉑類和紫杉烷類藥物，而免疫療法則根據CTLA-4抑制劑和PD-1抑制劑進行分類。化療療法包括近距離放射，手術選擇則涵蓋從部分胃切除術到全胃切除術。放射線治療標靶治療的分類反映了針對EGFR、HER2和VEGF路徑的治療。這些針對特定治療方法的區分會影響臨床治療順序、不利事件管理以及基於生物標記的患者選擇。

對美洲、歐洲、中東和非洲以及亞太地區的支付方結構、監管管道和交付能力如何影響治療的採用和獲取進行區域分析。

區域臨床實務模式、監管路徑和醫療保健系統資金籌措影響胃癌治療方法的研發、核准和實施。在美洲，私人和公共保險公司並存，不斷發展的價值導向醫療體系，以及集中式卓越中心推動著高成本標靶治療和免疫腫瘤藥物的早期應用，這些因素共同影響著臨床應用。該地區的醫療服務提供者通常優先考慮療效指標和真實世界數據（REW）的生成，以支援報銷申請並最佳化上市後應用程式。

策略性概述影響胃癌治療藥物的研發、取得和分銷的競爭動態、夥伴關係模式和商業化重點。

胃癌治療領域的競爭動態反映了一個多元化的生態系統，涵蓋了成熟企業、高度專業化的生物技術創新者以及學術機構和合約研究組織（CRO）的合作網路。成熟企業不斷最佳化現有產品組合，拓展適應症、最佳化治療方案定位，並將標靶治療與細胞毒性藥物和免疫調節劑結合。同時，中小型創新企業正致力於開發以機制主導導向、針對特定分子亞群的候選藥物，並利用富含生物標記的臨床試驗設計來驗證其差異化的臨床療效。

為開發商、支付方和供應商提供可操作且優先考慮的建議，以協調臨床開發、供應彈性和商業化，從而產生可衡量的影響。

行業領導者必須採取務實且具有前瞻性的方法，將科學進步轉化為永續的臨床和商業性成果。首先，將臨床開發計畫與基於生物標記的患者選擇和適應性試驗設計相結合，既能節約資源，又能提高證明療效顯著的可能性。此外，製藥公司應積極設計實證項目，涵蓋隨機對照試驗和真實世界研究，以滿足各司法管轄區監管機構和支付方的期望。

我們採用穩健的混合方法研究途徑，結合專家訪談、臨床文獻綜述和跨細分分析，得出檢驗且可操作的見解。

本分析的調查方法透過整合多源證據並結合專家驗證的解讀，確保了其嚴謹性。主要資料來源包括對腫瘤科醫生、首席藥劑師、支付方代表和臨床實踐經理的結構化檢驗，這些訪談揭示了真實世界的診療模式、推廣應用的障礙以及證據需求。二級資訊來源包括同儕審查的臨床文獻、臨床試驗註冊資料、監管指導文件和總結的公開文件，從而建構出治療機制、安全性特徵和試驗終點的準確整體情況。

一項權威的綜合分析強調了整合臨床、商業和營運策略的必要性，以將創新轉化為可及且永續的胃癌治療方法。

胃癌治療正朝著更個人化和多元化的模式轉變，這需要臨床證據、供應鏈、保險框架和醫療服務體系的協調配合。標靶治療和免疫腫瘤學的進步正在創造新的臨床可能性，但要最大限度地發揮其潛力，需要在診斷、患者支持和真實世界數據（REW）收集方面進行協調投資。此外，給藥途徑、分銷管道和區域監管差異等營運因素也會顯著影響這些療法的應用速度和普及程度。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的胃癌治療市場

  • 化療
    • 基於Fluorouracil的
    • 含鉑類藥物
    • 基於紫杉烷類藥物
  • 免疫療法
  • 放射線治療
    • 近距離放射治療
    • 遠端輻射
  • 外科手術
    • 部分切除術
    • 全胃切除術
  • 分子標靶治療

第9章 胃癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：胃癌治療市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第11章：胃癌治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：胃癌治療市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第13章 胃癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 胃癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 胃癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國胃癌治療市場

第17章：中國胃癌治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celltrion Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-F927BA461E32

The Stomach Cancer Treatment Market was valued at USD 6.10 billion in 2025 and is projected to grow to USD 6.71 billion in 2026, with a CAGR of 11.16%, reaching USD 12.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.10 billion
Estimated Year [2026] USD 6.71 billion
Forecast Year [2032] USD 12.79 billion
CAGR (%) 11.16%

A comprehensive orientation to evolving stomach cancer treatment dynamics, unmet clinical needs, therapeutic innovation, and stakeholder priorities shaping care practices

Stomach cancer treatment is at an inflection point where decades of incremental improvements intersect with a new cadence of therapeutic innovation and health system recalibration. Patients, clinicians, and payers are navigating increasingly complex care pathways that combine traditional modalities such as surgery and chemotherapy with expanding use of targeted agents, immuno-oncology therapies, and advanced radiotherapeutic techniques. As a result, clinical decision trees now require integration of histologic subtyping, molecular profiling, and patient-centered considerations including route of administration and care setting.

Moreover, the therapeutic conversation is shifting from single-modality dominance toward multi-modality sequencing and combination regimens, which demand cross-disciplinary coordination and refined clinical guidelines. This shift is accompanied by evolving regulatory expectations and reimbursement mechanisms that place greater emphasis on real-world evidence, value demonstration, and health economic models. Operationally, providers must reconcile inpatient and outpatient capacity planning as oral agents and homecare support change utilization patterns. In parallel, clinical research priorities are emphasizing biomarkers that predict response across adenocarcinoma, gastrointestinal stromal tumors, and other histologic variants, prompting a more granular approach to trial design and therapeutic targeting.

Taken together, these dynamics create both urgency and opportunity for stakeholders aiming to optimize patient outcomes while managing resource constraints. Looking ahead, the trajectory of innovation will be shaped by how well clinical evidence, payer frameworks, and delivery systems align to support personalized, accessible, and sustainable stomach cancer care.

How scientific breakthroughs, evolving administration practices, and health system trends are reshaping clinical pathways and investment priorities for stomach cancer care

The landscape of stomach cancer treatment is being transformed by a confluence of scientific breakthroughs, clinical practice evolution, and systemic shifts in care delivery. Precision medicine advances have accelerated the identification of actionable targets, creating opportunities for targeted therapies such as EGFR, HER2, and VEGF inhibitors to be integrated into standard regimens. At the same time, immunotherapy agents, including CTLA-4 and PD-1 inhibitors, are reshaping expectations for durable responses in subsets of patients, prompting recalibration of endpoint selection and long-term outcome measurement.

Concurrently, clinical practice is adapting to new administration routes and settings: the increasing adoption of oral formulations has implications for adherence monitoring and outpatient management, while radiotherapy modalities like brachytherapy and external beam are being refined through image-guided techniques that enhance precision. Surgical practice is also evolving, with nuanced decisions between partial and total gastrectomy informed by tumor location, stage, and patient comorbidity. These therapeutic shifts intersect with broader health-system trends such as digital health-enabled monitoring, expanded homecare capabilities, and pharmacy channel diversification that includes hospital, retail, and online options.

Ultimately, the most consequential transformations will emerge where scientific innovation, regulatory flexibility, and payer alignment converge to enable timely adoption of clinically meaningful therapies. Stakeholders who anticipate these inflection points and operationalize cross-functional readiness will be best positioned to translate therapeutic advances into improved patient outcomes and sustainable care delivery.

Qualitative analysis of how recent U.S. tariff adjustments are influencing supply chain resilience, sourcing strategies, and procurement practices across stomach cancer therapeutics

Policy changes and trade measures can ripple through drug supply chains, procurement costs, and manufacturer pricing strategies in ways that materially affect availability and access to therapies. Recent tariff proposals and adjustments in the United States have introduced considerations that extend beyond immediate cost differentials to include supplier diversification, contracting terms, and inventory strategies. Because many active pharmaceutical ingredients and finished products rely on global manufacturing networks, tariff-driven cost pressures can accelerate efforts to reshore manufacturing, secure alternative suppliers, or renegotiate long-term agreements to cap input volatility.

In practice, health systems and pharmacy channels must weigh potential cost implications against clinical imperatives that prioritize continuity of care. For example, if certain intravenous agents are sourced through affected import routes, hospitals and specialty clinics may consider adjusting procurement windows, increasing buffer stocks, or seeking therapeutic alternatives to avoid treatment disruptions. Simultaneously, manufacturers facing higher import costs may re-evaluate pricing strategies, discounting tactics, or market prioritization decisions, which in turn influence payer negotiations and formulary placement.

Beyond immediate procurement effects, tariffs can catalyze strategic shifts such as accelerated investment in local manufacturing capacity, restructured distribution footprints that favor resilient domestic supply chains, and closer collaboration between suppliers and large buying entities to share risk. These adaptive responses will be shaped by the timing and permanence of tariff measures, as well as by parallel regulatory and payer signals that determine clinical and commercial feasibility for alternative sourcing or domestic production investments.

In-depth segmentation analysis showing how modality, administration route, distribution channel, disease stage, end user, and histologic type jointly determine therapeutic and commercial strategies

A nuanced segmentation lens reveals how therapeutic decisions and commercial strategies must align with clinical heterogeneity and care settings. Treatment modalities span chemotherapy, immunotherapy, radiotherapy, surgery, and targeted therapy, and each modality contains clinically meaningful subgroups; chemotherapy encompasses fluorouracil-based, platinum-based, and taxane-based regimens, while immunotherapy is distinguished by CTLA-4 and PD-1 inhibitor classes. Radiotherapy practice includes brachytherapy and external beam approaches, and surgical options range from partial gastrectomy to total gastrectomy. Targeted therapy differentiation reflects agents directed at EGFR, HER2, and VEGF pathways. These modality-specific distinctions influence clinical sequencing, adverse event management, and biomarker-driven patient selection.

Route of administration further shapes adherence, administration costs, and care setting decisions, with intravenous and oral pathways creating distinct monitoring and support needs. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy determine access patterns, dispensing controls, and reimbursement workflows, while stage-specific considerations across Stage I through Stage IV guide the balance between curative intent and palliative optimization. End users encompass homecare, hospitals, and specialty clinics, each with unique capacity constraints and care coordination models that affect therapy adoption. Histologic diversity-adenocarcinoma, carcinoid tumors, gastrointestinal stromal tumors, and lymphoma-adds another layer of clinical differentiation that informs trial eligibility and therapeutic targeting.

Taken together, segmentation insights indicate that commercial strategies and clinical guidelines must be highly tailored. Manufacturers and providers should align product development and delivery models with the modality-specific efficacy profile, administration route, and distribution realities to achieve the greatest clinical impact and operational fit within heterogeneous care ecosystems.

Regional analysis of how payer structure, regulatory pathways, and delivery capacity in the Americas, Europe Middle East & Africa, and Asia-Pacific shape treatment adoption and access

Regional patterns in clinical practice, regulatory pathways, and health-system financing shape how therapies for stomach cancer are developed, approved, and delivered. In the Americas, clinical adoption is influenced by a mix of private and public payers, evolving value frameworks, and concentrated centers of excellence that drive early uptake of high-cost targeted and immuno-oncology agents. Providers in this region often emphasize outcome measurement and real-world evidence generation to support reimbursement discussions and to optimize post-market utilization.

In Europe, the Middle East & Africa region, regulatory harmonization across markets and divergent reimbursement processes create a mosaic of access dynamics. Some jurisdictions prioritize national health technology assessment frameworks that require rigorous health economic demonstration, while others emphasize expedited access mechanisms for novel therapies. These differences lead manufacturers to adopt regionally differentiated market entry tactics and pricing strategies to reflect heterogeneous affordability and prioritization.

Across Asia-Pacific, demographic trends, growing oncology infrastructure, and expanding diagnostic capabilities are accelerating demand for biomarker-driven treatments and oral therapies that can be managed in outpatient settings. Regional manufacturing hubs and evolving regulatory pathways also influence procurement and distribution approaches. Collectively, these geographic distinctions underline the importance of tailored country-level strategies that reconcile clinical evidence, regulatory timing, payer expectations, and local delivery capacity to achieve sustained access and uptake.

A strategic overview of competitive dynamics, partnership models, and commercialization priorities that determine success across development, access, and scale for stomach cancer therapies

Competitive dynamics in stomach cancer treatment reflect a multifaceted ecosystem of long-established incumbents, specialty biotech innovators, and collaborative networks spanning academic centers and contract research organizations. Established players continue to optimize existing portfolios through label expansions, line-of-therapy positioning, and combination strategies that pair targeted agents with cytotoxic backbones or immune modulators. At the same time, smaller and mid-size innovators are advancing mechanism-driven candidates that address specific molecular subgroups, leveraging biomarker-enriched trial designs to demonstrate differentiated clinical benefit.

Strategic partnerships and licensing agreements remain central to accelerating development timelines and expanding geographic reach, particularly where regulatory heterogeneity demands localized trials or bridging studies. Moreover, co-development arrangements that blend clinical expertise with commercialization capabilities help de-risk late-stage programs and enable access to specialized distribution channels. Parallel to these collaborations, service providers focused on patient support, diagnostics, and digital adherence tools are becoming integral to therapeutic value propositions, especially for oral agents and homecare models.

From a commercialization perspective, the interplay between pricing strategy, evidence generation, and payer engagement is critical. Companies that invest in robust real-world evidence collection, health economic modeling, and stakeholder education are better positioned to secure favorable formulary placement and to demonstrate value across diverse care settings. Ultimately, competitive success will hinge on the ability to deliver clinically meaningful outcomes at scale while managing cost and operational complexity across multiple channels and regions.

Practical and prioritized recommendations for developers, payers, and providers to align clinical development, supply resilience, and commercialization for measurable impact

Industry leaders must adopt pragmatic, forward-looking moves to translate scientific advances into durable clinical and commercial outcomes. First, aligning clinical development plans with biomarker-driven patient selection and adaptive trial architectures can increase the probability of demonstrating meaningful benefit while conserving resources. Manufacturers should also proactively design evidence-generation programs that encompass both randomized controlled trials and real-world studies to satisfy regulatory and payer expectations across jurisdictions.

Operationally, investing in supply chain resilience will mitigate risks associated with global sourcing and tariff-induced disruptions; this includes diversifying supplier networks, enhancing inventory management, and exploring localized manufacturing partnerships where feasible. Commercial teams should tailor go-to-market approaches by modality and administration route, recognizing that oral agents may require more robust adherence and patient support infrastructure, whereas intravenous or surgical-centric therapies depend on hospital and specialty clinic readiness. Engagement with distribution partners across hospital pharmacy, online pharmacy, and retail pharmacy channels must be synchronized to ensure seamless patient access.

Finally, pursue cross-stakeholder collaborations that integrate diagnostics, digital health tools, and payer engagement early in development. Building compelling health economic models and collecting longitudinal outcomes data will facilitate payer conversations and support differentiated positioning. By executing these strategic priorities, leaders can improve patient outcomes while securing sustainable commercial pathways.

Robust mixed-methods research approach combining expert interviews, clinical literature review, and cross-segmentation analysis to produce validated, actionable insights

The research methodology underpinning this analysis combines a multi-source evidence synthesis with expert-validated interpretation to ensure actionable rigor. Primary inputs include structured interviews with oncologists, pharmacy directors, payer representatives, and clinical operations leaders, which inform real-world care patterns, adoption barriers, and evidence needs. Secondary sources encompass peer-reviewed clinical literature, clinical trial registries, regulatory guidance documents, and aggregated public filings to construct an accurate picture of therapeutic mechanisms, safety profiles, and trial endpoints.

Analytical techniques applied include cross-segmentation mapping to align therapeutic modalities with administration routes, distribution channels, disease stages, end-user contexts, and histologic subtypes. Scenario analysis and sensitivity checks were used to test assumptions around supply chain disruptions and policy shifts, while qualitative synthesis grounded recommendations in stakeholder priorities and operational feasibility. Wherever possible, findings were triangulated across multiple data sources and validated through expert advisory consultations.

The research team adhered to transparent documentation of data provenance, interview protocols, and analytic assumptions to ensure reproducibility and to support client-specific customizations. Ethical considerations guided stakeholder engagement, and all primary data collection was conducted with appropriate confidentiality measures. This methodological foundation supports robust, pragmatic insights for stakeholders navigating the evolving stomach cancer treatment landscape.

Conclusive synthesis emphasizing the necessity of integrated clinical, commercial, and operational strategies to translate innovation into accessible and sustainable stomach cancer care

Stomach cancer care is moving toward a more personalized, multi-modality model that requires alignment across clinical evidence, supply chains, payer frameworks, and care delivery systems. Advances in targeted therapies and immuno-oncology are creating new clinical possibilities, but realizing their full potential depends on coordinated investments in diagnostics, patient support, and real-world evidence generation. Additionally, operational factors such as administration routes, distribution channels, and regional regulatory differences will materially influence the pace and breadth of adoption.

Stakeholders that proactively integrate scientific strategy with pragmatic commercialization and supply chain planning will be best positioned to deliver meaningful improvements in outcomes. This requires a holistic perspective that considers histologic heterogeneity, disease stage, and end-user capabilities while also anticipating policy and trade developments that affect access. In short, success will be defined by the ability to translate therapeutic promise into accessible, economically sustainable care pathways that are responsive to evolving clinical and payer expectations.

As the field evolves, continuous monitoring of clinical trial results, regulatory decisions, and real-world performance will be essential to refine strategies and to capture windows of opportunity for differentiated therapies. The path forward combines scientific rigor with operational adaptability to ensure that innovation equitably reaches patients who need it most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Stomach Cancer Treatment Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Fluorouracil-Based
    • 8.1.2. Platinum-Based
    • 8.1.3. Taxane-Based
  • 8.2. Immunotherapy
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam
  • 8.4. Surgery
    • 8.4.1. Partial Gastrectomy
    • 8.4.2. Total Gastrectomy
  • 8.5. Targeted Therapy

9. Stomach Cancer Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Stomach Cancer Treatment Market, by Stage

  • 10.1. Stage I
  • 10.2. Stage Ii
  • 10.3. Stage Iii
  • 10.4. Stage Iv

11. Stomach Cancer Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Stomach Cancer Treatment Market, by End User

  • 12.1. Homecare
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Stomach Cancer Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Stomach Cancer Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Stomach Cancer Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Stomach Cancer Treatment Market

17. China Stomach Cancer Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Bristol Myers Squibb Company
  • 18.10. Celltrion Inc.
  • 18.11. Daiichi Sankyo Company, Limited
  • 18.12. Eisai Co., Ltd.
  • 18.13. Eli Lilly and Company
  • 18.14. F. Hoffmann-La Roche Ltd.
  • 18.15. Johnson & Johnson
  • 18.16. Merck & Co., Inc.
  • 18.17. Novartis AG
  • 18.18. Otsuka Pharmaceutical Co., Ltd.
  • 18.19. Pfizer Inc.
  • 18.20. Sanofi S.A.
  • 18.21. Taiho Pharmaceutical Co., Ltd.
  • 18.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STOMACH CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL STOMACH CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY FLUOROURACIL-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PLATINUM-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TAXANE-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY PARTIAL GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TOTAL GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GCC STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 197. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 206. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL STOMACH CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA STOMACH CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA STOMACH CANCER TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)